Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

摘要: Chimeric antigen receptor (CAR) T-cell technology has seen a rapid development over the last decade mostly due to potential that these cells may have in treating malignant diseases. It is generally accepted principle very few therapeutic compounds deliver clinical response without treatment-related toxicity, and studies shown CAR T-cells are not an exception this rule. While large multinational drug companies currently investigating role of hematological oncology, such cellular therapies being recognized worldwide as they expected expand patient support establishment immune memory, provide continuous surveillance prevent and/or treat relapse, keep targeted cell subpopulation check. In article, we present possible advantages using acute lymphoblastic leukemia, presenting current knowledge their preclinical early trial use. Thus, article first presents main present-day on standard care for leukemia. Afterward, presented about use cancer immunotherapy, describing design, molecular constructs, data murine models properly explain background Last, but certainly least, immunotherapy B-cell both side effects.